Eli Lilly and Company (LLY) stock prices updated...

Eli Lilly and Company stock price, LLY

Eli Lilly and Company stock chart:

Eli Lilly and Company close price: 80.36

Stock price forecast:

DOWN TO -13.22%
Target: 69.74

Total forecasts: 90
Reached: 65 (72.22%)

Total Win: 177.03 (251.13%)

DaysForecastsReached%Reached points%InvestedUnreached%Total%

Showing 1-10 of 469 items.
Date of ForecastStock PriceTarget PriceForecast Reached Date

Eli Lilly and Company latest news:

  • 12/09/2016 05:08:27

    Eli Lilly and AstraZeneca to co-develop Alzheimer's Disease treatment

    Eli Lilly & Co. and AstraZeneca Plc said Friday they have entered an agreement to jointly develop an Alzheimer's Disease treatment. The companies will work together on MEDI1814, an antibody selective for amyloid-beta 42, which is currently in Phase 1 trials. As part of the agreement, Eli Lilly will make an upfront payment of $30 million to AstraZeneca. Eli Lilly will book a pretax charge of $30 million in the fourth quarter, equal to an after-tax charge of 2 cents a share. Eli Lilly shares were not yet active premarket. AstraZeneca ADRs were up 1.4%, but are down 26% in the year so far, while the S&P 500 has gained about 10%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 12/08/2016 14:06:55

    Biogen shares rise 1.6% on leaked Alzheimer's drug data

    iogen Inc. shares rose 1.6% in afternoon trade after data from its Alzheimer's drug was leaked. Biogen has been the particular target of investor interest after the recent high-profile failure of Eli Lilly's Alzheimer's drug. Biogen shares have dropped 5.5% year-to-date, compared with a 9.9% rise in the S&P 500 . Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 12/02/2016 11:32:14

    Lilly's diabetes drug Jardiance cuts risk of cardiovascular death: FDA

    Dec 2 (Reuters) - The U.S Food and Drug Administration said on Friday it had approved Eli Lilly and Co and Boehringer Ingelheim Pharmaceuticals Inc's drug, Jardiance, to reduce the risk of cardiovascular death in patients with type 2 diabetes.

  • 11/25/2016 05:09:50

    What Eli Lilly's hard fall in Alzheimer's treatment race means for its competitors

    Late-stage Alzehimer's drug failure could hurt Biogen, Merck. Eli Lilly and Company (LLY) shares plunged 11% Wednesday to a two-year low, after the company's treatment for people with mild dementia due to Alzheimer's disease failed to meet the primary endpoint in a late-stage clinical trial. The failure, which several Wall Street analysts said was disappointing, could have negative implications for Eli Lilly's Alzheimer's portfolio and competitors including Biogen Inc. and...

  • More trends:

    Ellie MaeELLI | Ellington Financial LLCEFC | Ellington Residential Mortgage REITEARN | Embotelladora Andina S.A.AKO.A | Embotelladora Andina S.A.AKO.B | Embraer-Empresa Brasileira de AeronauticaERJ | EMC CorporationEMC | EMCOR GroupEME | Emerge Energy Services LPEMES | Emergent BiosolutionsEBS |